ClexBio

ClexBio is a preclinical-stage biotechnology company that develops next-generation tissue therapeutics for regenerative medicine. Its proprietary VivoSet technology platform utilizes injection molding to manufacture fully vascularized, cell-synthesized tissues that function as a thriving microenvironment. By creating tissues with microvascular networks and a cell-synthesized extracellular matrix, the company aims to restore lost organ function without the need for artificial materials, thereby reducing the risk of fibrotic responses. Its product pipeline includes therapeutic candidates for acute liver failure, Type 1 diabetes, and cardiac regeneration, which are designed to integrate seamlessly with host vasculature to provide lasting therapeutic benefits.

This technology addresses significant medical challenges, particularly for patients with chronic diseases who have limited treatment options beyond organ transplantation. By enabling the scalable, automated production of functional tissue units, ClexBio seeks to improve patient outcomes in fields such as hepatology and cardiology. The company’s approach is intended to overcome the limitations of traditional cell therapies and drugs by restoring complex physiological functions. Supported by venture and foundation investments, ClexBio is currently focused on advancing its lead programs through preclinical development to address major health conditions with high unmet needs.